Results 51 to 60 of about 9,047 (170)

Generic drugs: myths, facts, and limitations

Italian Journal of Medicine, 2012
Bioequivalence (BE) has always been an important pharmaceutical area, particularly (but not solely) in Mediterranean region, where the use of generic drugs is a relatively recent development. The lack of new therapeutic molecules has concentrated primary
Antonio Marzo, Elisabetta Porro, Anna Barassi   +2 more
doaj   +1 more source

Advancing pharmacometrics in Africa—Transition from capacity development toward job creation

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 407-419, March 2025.
Abstract Trained pharmacometricians remain scarce in Africa due to limited training opportunities, lack of a pharmaceutical product development ecosystem, and emigration to high‐income countries. The Applied Pharmacometrics Training (APT) fellowship program was established to address these gaps and specifically foster job creation for talent retention.
Goonaseelan (Colin) Pillai, Samer Mouksassi, Innocent G. Asiimwe, Craig R. Rayner, Steven Kern, Phumla Sinxadi, Paolo Denti, Eric Decloedt, Catriona Waitt, Bernhards R. Ogutu, Rik de Greef   +10 more
wiley   +1 more source

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

Phytotherapy Research, EarlyView.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee, Yu Jin So, Il‐Joo Jo, Ji Yong Jang, Tae Han Yook, Jun Ho Lee, Sung Wook Kim, Kangwook Lee, Soo Jung Park, Gabsik Yang   +9 more
wiley   +1 more source

Gliclazide Enhances Exercise Performance and Recovery of Muscle Strength in Healthy Trained Individuals: A Randomized Controlled Trial

European Journal of Sport Science, Volume 26, Issue 4, April 2026.
ABSTRACT To examine the acute effect of gliclazide on exercise performance and recovery of muscle strength in healthy participants. We conducted a randomized, double‐blind, placebo‐controlled crossover clinical trial in 44 strength‐trained men. They were allocated to gliclazide modified release (MR) (90 mg, 8h before exercise sessions) or placebo ...
Jocelito Bijoldo Martins, Thiago Dipp, Beatriz D. Schaan, Alexandre Machado Lehnen   +3 more
wiley   +1 more source

Influence of Different Populations on Pharmacokinetic Bioequivalence Results: Can We Extrapolate Bioequivalence Results from One Population to Another?

Journal of Pharmacy & Pharmaceutical Sciences, 2020
Purpose: Over the last 15 years, an ever-increasing proportion of pharmacokinetic bioequivalence studies for European/North American generic submissions appeared to have been conducted in geographical/ethnic populations other than those for which the ...
Deniz Ozdin, Murray P. Ducharme, France Varin, Anders Fuglsang, Dina Al-Numani   +4 more
doaj   +1 more source

Toward the harmonization of bioequivalence guidelines in Europe: Commentary on the state of the art and future priorities under ICH M13A for immediate‐release oral forms

British Journal of Clinical Pharmacology, EarlyView.
Domenico Nocera, Giusi Forastiero, Andrea Logreco, Alessia Proietti, Antonio Galluccio, Carlotta Lunghi, Elisabetta Poluzzi, Fabrizio De Ponti   +7 more
wiley   +1 more source

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

Muscle &Nerve, Volume 73, Issue 4, Page 534-543, April 2026.
ABSTRACT Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is currently approved in the US for treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed that IV edaravone slows physical functional decline.
Angela Genge, Jeffrey Rothstein, Shari De Silva, Lorne Zinman, Marvin Chum, Adriano Chiò, Gen Sobue, Masashi Aoki, Hiide Yoshino, Manabu Doyu, Daniel Selness, Vesna Todorovic, Manabu Hirai, Nissim Sasson, Fumihiro Takahashi, Michelle Cecić, Art Wamil, Stephen Apple   +17 more
wiley   +1 more source

Nanocarriers based therapy and diagnosis of brain diseases: cross the blood-brain barrier

Science and Technology of Advanced Materials
The blood-brain barrier (BBB) is the protective interface that isolates the central nervous system from circulating blood, which restricts approximately 98% of small molecule drugs and nearly all large molecules from entering the brain.
Lijun An, Jinwei Zhang, Xiaobo Wang, Yuanyuan Ge, Kunhui Sun, Junlin Dong, Ping Wang, Wei Li, Meifang Li, Xuelei Hu, Bing Wang, Xie-An Yu   +11 more
doaj   +1 more source

The implementation of the bioequivalence certification policy in Chile: An analysis of market authorization data.

PLoS ONE, 2019
BackgroundAffordability is a key barrier to access to medicines. Generic medicines policies can address this barrier and promote access. Successful uptake of generic medicines depends, in part, on ensuring that these products are interchangeable with ...
Warren A Kaplan, Jorge Cárdenas, Cristián Mansilla, Tatiana Tobar, Veronika J Wirtz   +4 more
doaj   +1 more source

A Clinically Relevant Drug Interaction Between Busulfan and Rifampin in the Setting of Hematopoietic Stem Cell Transplant Conditioning

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
ABSTRACT Busulfan is an alkylating agent used in combination with other chemotherapeutic agents and has become a common component of conditioning regimens prior to hematopoietic stem cell transplantation. Busulfan has a very narrow therapeutic index corresponding to the area under the plasma concentration–time curve, with supra‐therapeutic busulfan ...
Colleen Drangines, Janet Laquet, Ranju Kunwor   +2 more
wiley   +1 more source